FGF21 and metabolic dysfunction-associated steatotic liver disease: Additionally, this treatment caused repression of genes coding for cholesterol and BA metabolism, and the results are similar between FGF21 treated DIO mice and MASLD patients with increased FGF21 expression (see Figures 5F, S6 and S7).